Crucell NV (CRXL) Posts Q3 EPS of €$0.15, In-Line with Street; Reiterates Guidance
More News related to CRXL
- 2010 IR Global Rankings: Invitation for Investors and Analysts Vote for Companies with the Best IR Program and for the Best IR Officer
- Crucell launches global brand to reflect and reinforce its leading position in healthcare innovation
- TapImmune (TPIV) In License Agreement with Crucell (CRXL)
- UBS Upgrades Crucell NV (CRXL) to Buy
- Crucell NV (CRXL) Posts Q3 EPS of €$0.15, In-Line with Street; Reiterates Guidance
Crucell NV (NASDAQ: CRXL) reports Q3 EPS of €0.15, even with the analyst estimate of €0.15. Revenue for the quarter was €94.30 million, which compares to the estimate of €102.85 million.
Reiterates 2009 full year guidance reiterated: total revenues and other operating income expected to grow 20% in constant currencies; operating profit for 2009 expected to improve significantly compared to 2008; strong cash position.
Related Categories
EarningsStocks Mentioned
-0.58Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
